Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 4/20 | 0.33 |
| ▸ | WDR5 | P61964 | 8/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25529079 | 0.92 | ROCK2 (0.34) | ROCK2ROCK1F10CACNA1H | |
| SCHEMBL25528480 | 0.91 | ROCK2 (0.43) | ROCK2ROCK1F10KCNH2CACNA1I | |
| SCHEMBL25530204 | 0.91 | ROCK1 (0.35) | ROCK2ROCK1WDR5 | |
| SCHEMBL25528924 | 0.91 | CACNA1H (0.37) | ROCK2ROCK1F10CACNA1HWDR5 | |
| SCHEMBL25529088 | 0.90 | ROCK2 (0.35) | ROCK2ROCK1F10CACNA1H | |
| SCHEMBL25529084 | 0.89 | ROCK2 (0.34) | ROCK2ROCK1F10CACNA1HMAPK14 | |
| SCHEMBL25529070 | 0.89 | CACNA1H (0.33) | ROCK2ROCK1F10CACNA1HMAPK14 | |
| SCHEMBL25532600 | 0.89 | CACNA1H (0.33) | ROCK2ROCK1CACNA1HKCNH2 | |
| SCHEMBL25528621 | 0.89 | CACNA1H (0.36) | ROCK2ROCK1CACNA1H | |
| SCHEMBL25531285 | 0.89 | ROCK2 (0.33) | ROCK2ROCK1CACNA1H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023093787-A1 | BENZODIAZEPINE COMPOUND AND APPLICATION THEREOF AS RHO KINASE INHIBITOR | 成都奥睿药业有限公司 | 2023-06-01 | — | — | WO | disclosed |